The role of cytokines in polycystic ovarian syndrome

Gynecological Endocrinology

Volumn 29, Issue 6, 2013, Pages 536-540

  Ebejer, Krystle ^a   Calleja Agius, Jean ^a,b  

^a UNIVERSITY OF MALTA   (Malta)

^b MATER DEI HOSPITAL   (Malta)

Author keywords

Cytokines; Obesity; Polycystic ovary syndrome

Indexed keywords

ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; SIMVASTATIN; TESTOSTERONE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANDROGEN SYNTHESIS; ARTICLE; AUTOPHOSPHORYLATION; BODY MASS; CARBOHYDRATE METABOLISM; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DYSLIPIDEMIA; EOSINOPHIL; GLUCOSE INTOLERANCE; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER TOXICITY; LOW CALORY DIET; LOW DRUG DOSE; LYMPHOCYTE; MACROPHAGE; META ANALYSIS (TOPIC); MONOCYTE; MONONUCLEAR CELL; MONOTHERAPY; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); TESTOSTERONE BLOOD LEVEL;

ADULT; CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; HYPERANDROGENISM; INFLAMMATION; INSULIN RESISTANCE; MODELS, BIOLOGICAL; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 84877612175     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.760195     Document Type: Article

References (46)

1. Ascunion M, Calvo RM, San Milan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metabol 2000;85:2434-8
2. Stein F, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91
3. Glintborg D, Adersen M. An update on the pathogenesis, inflammation and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010;26:281-96
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-Term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25
5. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011;335:30-41
6. Cibula D, Cifkova R, Fanta M, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in peri-menopausal women with a history of the polycystic ovary syndrome. Human Reprod 2000;15:785-9
7. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 2002;9:451-8
8. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-Term follow-up: A retrospective cohort study. Clin Endocrinol 2000;52:595-600
9. González F. Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids 2012;77:300-5
10. González F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metabol 2006;91:1508-12
11. Xiong YL, Liang XY, Yang X, et al. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol 2011;159:148-50
12. Amato G, Conte M, Mazziotti G, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003;101:1177-82
13. Fulghesu AM, Sanna F, Uda, S, et al. IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance. Mediators Inflammat 2011;2011:389317; doi:10.1155/2011/ 389317; Epub 2011 Mar 20
14. Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: Their relationship to insulin resistance and body mass index. Dis Marker 2009; 26:163-70
15. Yang Y, Qiao J, Li R, Li MZ. Is interleukin-18 associated with polycystic ovary syndrome? Reprod Biol Endocrinol 2011;9:7-11
16. Kelly CCJ, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metabol 2001;86:2453-5
17. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6
18. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-154
19. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Human Reprod 2001;16:1255-60
20. Horejsi R, Möller R, Racki S, et al. Android subcutaneous tissue adipose topography in lean and obese women suffering from PCOS: Comparison with type 2 diabetic women. Am J Phys Anthropol 2004;124:275-81
21. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflammat 2010;2010:758656; doi:10.1155/2010/758656; Epub 2010 Apr 8
22. Moshage HJ, Roelofs HMJ, van Pelt JF, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988;155:112-7
23. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107:671-4
24. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: A systematic review and metaanalysis. Fertil Steril 2011;95:1048-58.e2
25. Cortón M, Botella-Carretero JI, Benguría A, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2007;92:328-37
26. González F, Minium J, Rote NS, Kiwan JP. Hyperlycemia alters tumor necrosis factor-A release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2005;90:5336-42
27. González F, Rote NS, Minium J, Kirwan JP. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-A release in obese women with polycystic ovary syndrome. J Endocrinol 2006; 188:521-9
28. Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-A stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod 1999;61:993-8
29. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metabol 1980;50:113-6
30. Bhatia V. Insulin resistance and inflammation in polycystic ovarian syndrome -newer concepts and role of insulin sensitizers. Curr Med Literat Gynecol Obstet 2006;11:49-57
31. Barber TM, McCarthy MI, Wass JAH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol 2006;65:137-45
32. O'Rourke RW, Kay T, Lyle EA, et al. Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin Exp Immunol 2006;146:39-46
33. ACOG Committee on Practice Bulletins -Gynecology. ACOG practice bulletin no. 108: Polycystic ovary syndrome. Obstet Gynecol 2009;114:936-49
34. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36: 150-11
35. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reprod 2006;21: 1426-32
36. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2003;88:4649-54
37. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562-6
38. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metabol 2005;90:60-5
39. Dhindsa G, Bhatia R, Dhindsa M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004;50:140-4
40. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters of polycystic ovary syndrome: Results of a prospective randomized trial. Fertil Steril 2006; 85:996-1001
41. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled study. J Clin Endocrinol Metabol 2009;94:103-8
42. Banaszewska B, Pawelczyk L, Spaczynski RZ,Duleba AJ. Comparison of simvastatin and metformin treatment of polycystic ovary syndrome: Prospective randomized trial. J Clin Endocrinol Metabol 2009;94:4938-45
43. Tait AS, Butts CL, Sternberg EM. The role of glucocorticoids and progestins in inflammatory, autoimmune and infectious disease. J Leukocyte Biol 2008; 84:924-31
44. Ansar Ahmed S, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985;121:531-51
45. Butts CL, Shukair SA, Duncan KM, et al. Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion. Int Immunol 2007;19:287-96
46. Banaszewska B, Spaczynski RZ, Ozegowska K, Pawelczyk L. The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome. Ginekolog Polska 2011;82:430-5